ALZHEIMERS DISEASE PATIENT REGISTRY

阿尔茨海默病患者登记处

• 批准号: 2049602
• 负责人: EMRE KOKMEN
• 金额: $ 74.87万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 1986
• 资助国家: 美国
• 起止时间: 1986-09-30 至 1999-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2049602
• 关键词: Alzheimer's disease; aging; autoimmune disorder; biomarker; brain disorder diagnosis; cognition; cognition disorders; cooperative study; dementia; diagnosis design /evaluation; disease /disorder proneness /risk; human data; human subject; human very old age (85+); immunopathology diagnosis; longitudinal human study; magnetic resonance imaging; medical records; memory disorders; mental disorder diagnosis; mental health epidemiology; neuropsychological tests; patient /disease registry; postmortem; psychological tests

The Mayo Clinic Alzheimer's Disease Patient Registry (ADPR) was developed in response to an RFA from NIA. Our ADPR provides longitudinal data which focus on epidemiological, clinical, neuropsychological, and pathological features of patients with dementia, and identifies those fulfilling the criteria of AD. There are two major components to this program. The "retrospective" approach utilizes the comprehensive medical records-linkage system at Mayo Clinic for the population of Rochester, Minnesota, and has identified more than 1200 dementia incidence cases over the 25-year period, 1960-1984. This component provides the only longitudinal incidence rates in North America. Numerous risk factors are being evaluated by comparing the incidence cases with age- and sex-matched controls from the community registry. Recent data from this project indicate that the incidence rates of AD may be increasing in the population 85 years and older. The ADPR "prospective" study has enrolled and is currently following over 250 pairs of dementia patients and their age- and sex-matched controls. This project provides information on the natural history of AD, as well as data useful for improving diagnostic techniques. The normal control cohort in this prospective study has also contributed to the development of a normative data base on several common neuropsychological tests for individuals aged 55 to 100 years. Our clinical and pathological comparisons for those 85 years and older in this cohort demonstrate that additional research to establish the boundaries between dementia and normal aging is needed. Having attained many of our objectives in the current project, we now propose new specific aims arising from our registry experience, designed to capitalize on the maturity of this data resource. These fall into four general areas: 1) to continue incidence, prevalence, and case-control studies to determine if the apparent increase in the incidence rate for AD in the old-old (85 + years) is not an artifact and, if not, to explore the reason(s) for the increase; 2) to determine the incidence and prevalence rates of vascular dementia based on recently published diagnostic criteria; 3) to prospectively study the natural history of AD in its late stages; and 4) to define cognitive, functional, and neuropathological boundaries between normal aging and early AD in the old-old. In addition, we will continue our case-control evaluations of putative etiologic factors, including the hypothetical association between autoimmune disease and AD. We will also continue our program in normative neuropsychology research and attempt to develop a screening method for detecting psychiatric comorbidity in community-dwelling dementia patients. Finally, consistent with the original goal of AD registries, we will continue to serve investigators within and outside the Mayo Clinic as a resource for subjects, tissues, and data from a clinically well-characterized cohort of dementia patients.

开发了梅奥诊所阿尔茨海默氏病患者登记册（ADPR） 响应NIA的RFA。我们的ADPR提供了纵向数据 专注于流行病学，临床，神经心理学和病理学 痴呆症患者的特征，并确定那些满足的人 广告的标准。该程序有两个主要组成部分。这 “回顾性”方法利用了全面的医疗记录连接 明尼苏达州罗切斯特的梅奥诊所的系统 在25年期间确定了1200多个痴呆症发病率病例 1960-1984。该组件提供了唯一的纵向发病率 北美。通过比较 社区年龄和性别匹配对照的发病案例 注册表。该项目的最新数据表明发病率 85岁以上的人口可能正在增加AD。 ADPR “前瞻性”研究已经招募，目前正在遵循250对超过250对 痴呆症患者及其年龄和性别匹配的对照。这个项目 提供有关AD自然历史的信息以及有用的数据 用于改进诊断技术。 在此中的正常控制队列 前瞻性研究也有助于发展规范 关于年龄的个体的几个常见神经心理学测试的数据基础 55至100年。我们对这85的临床和病理比较 在此队列中，年以上的年龄较大，这表明 建立需要痴呆和正常衰老之间的边界。 在当前项目中达到了许多目标，我们现在 提出由我们的注册表经验产生的新特定目标，旨在 利用此数据资源的成熟度。这些落入四个 一般区域：1）继续发病率，患病率和病例对照 研究以确定AD的发病率明显增加 在老年（85岁以上）中，不是人工制品，如果没有的话，探索 增加的原因； 2）确定发病率 基于最近发表的诊断标准的血管性痴呆率率； 3）前瞻性地研究AD的自然历史；和 4）定义认知，功能和神经病理学界限 在老年人的正常衰老和早期广告之间。此外，我们将 继续我们对假定病因的病例对照评估， 包括自身免疫性疾病与AD之间的假设关联。 我们还将继续我们的规范神经心理学研究计划 尝试开发用于检测精神病合并症的筛查方法 在社区居住的痴呆症患者中。最后，与 广告注册机构的最初目标，我们将继续为调查人员服务 梅奥诊所内外作为受试者，组织和 来自临床表征良好的痴呆症患者的数据。